Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shengmeng Di

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 9, 2019
Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 miceMuhua Chen, Ruixin Sun, Bizhi Shi, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2018
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion proteinZeyan Pan, Shengmeng Di, Bizhi Shi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 4, 2020
Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in MiceRuixin Sun, Hong Luo, Jingwen Su, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 1, 2017
A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T CellsXiuqi Wu, Bizhi Shi, Jiqin Zhang, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 9, 2019
Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 miceMuhua Chen, Ruixin Sun, Bizhi Shi, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2018
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion proteinZeyan Pan, Shengmeng Di, Bizhi Shi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 4, 2020
Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in MiceRuixin Sun, Hong Luo, Jingwen Su, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 1, 2017
A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T CellsXiuqi Wu, Bizhi Shi, Jiqin Zhang, et al.
Pageof 2